Uses and Administration of Telmisartan in Kenya
Telmisartan is an angiotensin II receptor antagonist type of antihypertensive drug used in Kenya in the management of hypertension.
Telmisartan is given by mouth. After an oral dose the hypotensive effect peaks within 3 hours and persists for at least 24 hours. The maximum hypotensive effect is achieved within about 4 to 8 weeks after initiating therapy.
In hypertension, telmisartan is given in an initial dose of 40 mg once daily. This may be increased, if necessary, to a maximum dose of 80 mg once daily. Lower doses should be considered in patients with hepatic impairment.
Adverse Effects/Side Effects of Telmisartan in Kenya
Adverse effects of Telmisartan have been reported to be usually mild and transient, and include dizziness, headache, and dose-related orthostatic hypotension. Hypotension may occur particularly in patients with volume depletion (for example those who have received high-dose diuretics). Impaired renal function and, rarely, rash, urticaria, pruritus, angioedema, and raised liver enzyme values may occur. Hyperkalaemia, myalgia, and arthralgia have been reported. Other adverse effects of Telmisartan that have been reported in Kenya include respiratory-tract disorders, back pain, gastrointestinal disturbances, fatigue, and neutropenia.